SGTX
Closed
Sigilon Therapeutics inc
22.47
0.00 (0.00%)
Last Update: 18 Aug 2023 16:30:00
Yesterday: 22.47
Day's Range: 22.47 - 22.47
Send
sign up or login to leave a comment!
When Written:
0.69
Sigilon Therapeutics Inc is a biotechnology company that focuses on developing cell therapies for chronic diseases. The company was founded in 2015 by a team of scientists from MIT, Harvard, and Boston Children's Hospital. Sigilon's approach involves encapsulating therapeutic cells in biocompatible materials, which protect the cells from the immune system and allow for sustained release of therapeutic proteins.
The company's lead product candidate is SIG-001, a cell therapy for hemophilia A that is currently in preclinical development. Sigilon also has programs in other chronic diseases, including type 1 diabetes, lysosomal storage disorders, and neurodegenerative diseases.
Sigilon has raised over $195 million in funding from investors such as Flagship Pioneering, Eli Lilly and Company, and the Bill and Melinda Gates Foundation. The company is headquartered in Cambridge, Massachusetts.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company's lead product candidate is SIG-001, a cell therapy for hemophilia A that is currently in preclinical development. Sigilon also has programs in other chronic diseases, including type 1 diabetes, lysosomal storage disorders, and neurodegenerative diseases.
Sigilon has raised over $195 million in funding from investors such as Flagship Pioneering, Eli Lilly and Company, and the Bill and Melinda Gates Foundation. The company is headquartered in Cambridge, Massachusetts.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!